Orphazyme A/S (ORPH)
Stock Price:
$10.35 USD
-0.35 (-3.23%)
Updated Oct 21, 2020 2:50 PM EDT - Market open
Key Info
| Market Cap |
358.95M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-64.09M |
| Shares Out |
34.66M |
| EPS (ttm) |
-1.85 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$10.35 |
| Previous Close |
$10.69 |
| Change ($) |
-0.35 |
| Change (%) |
-3.23% |
| Day's Open |
10.59 |
| Day's Range |
10.31 - 10.59 |
| Day's Volume |
27,229 |
| 52-Week Range |
9.51 - 11.07 |
More Stats
| Market Cap |
358.95M |
| Enterprise Value |
351.58M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
34.66M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
-1.85 |
| FCF / Share |
-2.46 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
6.78 |
| Revenue |
n/a |
| Operating Income |
-50.14M |
| Net Income |
-64.09M |
| Free Cash Flow |
-49.19M |
| Net Cash |
7.37M |
| Net Cash / Share |
0.21 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
-1,777.00% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions DKK.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -336 | -232 |
| Net Income | -337 | -230 |
| Shares Outstanding | 20.00 | 19.99 |
| Earnings Per Share | -16.87 | -11.49 |
| Operating Cash Flow | -327 | -235 |
| Capital Expenditures | -2.78 | -0.74 |
| Free Cash Flow | -330 | -236 |
| Cash & Equivalents | 124 | 395 |
| Total Debt | 74.23 | - |
| Net Cash / Debt | 49.36 | 395 |
| Assets | 181 | 441 |
| Liabilities | 128 | 53.10 |
| Book Value | 52.97 | 388 |
Numbers in millions DKK, except per-share numbers.
Company Details
| Full Name |
Orphazyme A/S |
| Country |
Denmark |
| Employees |
114 |
| CEO |
Kim Stratton |
Stock Information
| Ticker Symbol |
ORPH |
| Stock Exchange |
NASDAQ |
| Sector |
Health Technology |
| Industry |
Pharmaceuticals: Major |
| Unique Identifier |
NASDAQ: ORPH |
| IPO Date |
September 29, 2020 |
Description
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.